Dr. Christine S. Lee Acting Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. FDA | Official Website
Dr. Christine S. Lee Acting Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. FDA | Official Website
This is a 58.3% decrease from the number of companies inspected in the previous quarter, when 12 companies received 12 inspections.
Most of the companies inspected at the time were involved in the Biologics sector. The second most common type of company inspected worked in the Food and Cosmetics sector.
There were three companies in line with FDA regulations that do not need to adjust their management operations or regulatory/administrative actions. Two should take voluntary action to correct their management operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
| Company Name | Area of Business | Inspection Date | Result |
|---|---|---|---|
| Carter BloodCare | Biologics | 04/26/2024 | No Action Indicated (NAI) |
| Dairyland Produce, LLC | Food and Cosmetics | 04/01/2024 | Voluntary Action Indicated (VAI) |
| Garland Ventures, Ltd. | Food and Cosmetics | 04/19/2024 | Voluntary Action Indicated (VAI) |
| Texas Health Presbyterian Hospital of Dallas Blood Bank | Biologics | 05/24/2024 | No Action Indicated (NAI) |
| William R Lumry, M.D. | Biologics | 05/15/2024 | No Action Indicated (NAI) |
Alerts Sign-up